Peptides are more than just molecules used in labs. They have become popular drugs that can be made in large amounts and sent to all parts of the world. Peptides stand between small molecules and big biomolecules, and these have special structure and function advantages. So they are very promising in the world’s drug industry. People want better and safer ways to treat diseases, so peptide drugs have become an important part of new developments. People are now studying what they are, why they are important, what problems they have, and where they are going.
I. What Are Peptide Drugs?
Peptides are chain-shaped biomolecules. They are made of 2 to 50 amino acids connected by peptide bonds. This structure makes peptide simple like small molecules, and gives them biological activity like large proteins. If these peptide molecules work well to treat diseases, and meet strict standards, they are called peptide drugs.
For many years, many peptide drugs have been very important in medical treatment. Insulin was the world’s first recombinant peptide drug. It came out in 1982. It changed how diabetes is treated. It saved many lives around the world.
In recent years, GLP-1 receptor agonists like Semaglutide (Ozempic®) and Tirzepatide (Mounjaro®) have become famous all over the world. That is because they work very well. They are top drugs for weight loss and diabetes. Oxytocin helps with childbirth and breastfeeding. Leuprolide treats prostate cancer and endometriosis. Teriparatide helps with osteoporosis. All these drugs are very important in medicine. They meet medical needs that were not met before.
II. Why Are Peptide Drugs Getting More Attention?
Peptide drugs are getting more attention. That is because of four main good points.
First, Peptide can target specific things, and have few bad effects. Peptides can recognize targets that were hard to treat before.These targets include G protein-coupled receptors (GPCRs) and ion channels. They are more selective than small-molecule drugs. This means they act on the parts related to diseases. They do not harm healthy cells. So they cause fewer bad reactions.
Second, they work well, and are useful in medical treatment. For example, GLP-1 drugs can control blood sugar well.They also help patients lose 15% to 20% of their weight. They can even reduce the risk of heart and blood vessel diseases. Traditional drugs can hardly do these things.
Third, the time to develop peptides is shorter.Monoclonal antibodies usually take 5 to 10 years to go from development to preclinical testing. Peptide drugs only take 1 to 2 years. This includes designing their sequence and testing them before clinical use. So they can go from lab discovery to medical use faster.
Fourth, the market is growing very fast. The global peptide drug market is worth more than 50 billion US dollars. It grows at a rate of about 8% every year. In 2024, Semaglutide’s sales were more than 21.2 billion US dollars. It became the top prescription drug in the world. This shows that peptides have great commercial potential.
III. But Peptide Drugs Also Have “Problems”
Peptide drugs have good points. But they also face big problems. These problems stop Peptides from being used more widely. First, they are not easily absorbed when taken by mouth. Most peptide drugs are broken down by digestive enzymes in the stomach and intestines.
So they have to be injected under the skin or into a vein. Injecting is invasive. It makes patients less willing to take the drugs. This is especially true for those who need treatment for a long time.
Second, they do not last long in the body. Peptides are easily broken down by proteases in the body. So patients have to take them often. Or scientists have to change their structure in complex ways to make them work longer.
Third, making them is complicated. The main way to make them is solid-phase synthesis. This method is expensive. Purifying long-chain Peptide is technically hard. The quality control standards are very strict. All these things make the production cost high.
Fourth, there are many patent barriers. Big pharmaceutical companies often control core sequences, modification technologies, and delivery systems. This makes it hard for new companies to enter the market. To solve these problems, people are focusing on developing “long-acting” and “oral” technologies. They want to get past these difficulties. They want to make peptides more widely used.
IV. What Are the Future Directions?
The future of peptide drugs is shaped by several new trends. For long-acting technologies, fatty acid modification has worked well. For example, Semaglutide uses this modification.
It can work for a long time. So patients only need to take it once a week. For oral delivery, Oral Semaglutide (Rybelsus®) has been launched. This is a big breakthrough. It solves the problem of low oral absorption.
It makes it easier for patients to take the drug. Dual or multi-target peptides are another new direction. Tirzepatide is one of them. It activates both GLP-1 and GIP receptors. These two work together. So it is more effective than drugs that target only one thing. It opens up new ways to treat complex diseases.
About Ferbio
Ferbio advances intelligent bioreactor technology, building a bioreaction large model and an end-to-end platform for synthetic biology from “strain development to industrial production,” establishing a precision fermentation big data cloud that aggregates massive reaction data, enabling real-time monitoring, analysis, and prediction of fermentation parameters and substance changes, improving the efficiency and accuracy of synthetic biology research and development, and promoting intelligent, efficient, and sustainable development of the bio-industry.